Expression of Concern: Apolipoprotein D as a novel marker in human end-stage heart failure: a preliminary study (Biomarkers, 13, 5, (535-548), 10.1080/13547500802030363);Apolipoprotein D as a novel marker in human end-stage heart failure: A preliminary study

Biomarkers

Volumn 13, Issue 5, 2008, Pages 535-548

  Wei, Ying Jie ^a   Huang, Yin Xia ^a   Zhang, Xiao Ling ^a   Li, Jun ^a   Huang, Jie ^a   Zhang, Hao ^a   Hu, Sheng Shou ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Apolipoprotein D; Heart failure; Marker

Indexed keywords

APOLIPOPROTEIN D; MESSENGER RNA; RNA;

ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; GENE EXPRESSION REGULATION; HEART FAILURE; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

HOMO SAPIENS;

EID: 47949090706     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/1354750X.2020.1751942     Document Type: Erratum

References (29)

1. Barth, AS, Kuner, R., Buness, A., Ruschhaupt, M., Merk, S. Zwermann, L. et al. (2006) Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. Journal of the American College of Cardiology, 48, pp. 1610-1617.
2. Boyles, JK, Notterpek, LM, Wardell, MR Rall, SC et al. (1990) Identification, characterization, and tissue distribution of apolipoprotein D in the rat. Journal of Lipid Research, 31, pp. 2243-2256.
3. Camato, R., Marcel, YL, Milne, RW, Lussier-Cacan, S. and Weech, PK (1989) Protein polymorphism of a human plasma apolipoprotein D antigenic epitope. Journal of Lipid Research, 30, pp. 865-875.
4. Cermelli, S., Zerega, B., Carlevaro, M., Gentili, C., Thorp, B. Farquharson, C. et al. (2000) Extracellular fatty acid binding protein (Ex-FABP) modulation by inflammatory agents: 'physiological' acute phase response in endochondral bone formation. European Journal of Cell Biology, 79, pp. 155-164.
5. Crowther, JR (1995) ELISA. Theory and Practice. Methods in Molecular Biology, 42, pp. 1-223.
6. Dunlap, ME (2007) New studies influencing treatment of heart failure. Pharmacotherapy, 27, pp. 3S-11S.
7. Flower, DR (1994) The lipocalin protein family: A role in cell regulation. FEBS Letters, 354, pp. 7-11.
8. Greenberg, B. (2007) Can We IMPROVE-CHF management by measuring natriuretic peptides?. Circulation, 115, pp. 3045-3047.
9. Hunter, SB, Varma, V. and Shehata, B. (2005) Apolipoprotein D expression in primary brain tumors: Analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. Journal of Histochemistry & Cytochemistry, 53, pp. 963-969.
10. Hwang, JJ, Allen, PD, Tseng, GC, Lam, CW, Fananapazir, L. Dzau, VJ et al. (2002) Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiological Genomics, 10, pp. 31-44.
11. Kies, P., Bootsma, M. and Bax, J. (2006) Arrhythmogenic right ventricular cardiomyopathy: Screening, diagnosis, and treatment. Heart Rhythm, 3, pp. 225-234.
12. Kittleson, MM, Minhas, KM, Irizarry, RA, Ye, SQ, Edness, G., Breton, E., Conte, JV, Tomaselli, G., Garcia, JGN and Hare, JM (2005) Gene expression analysis of ischemic and nonischemic cardiomyopathy: Shared and distinct genes in the development of heart failure. Physiological Genomics, 21, pp. 299-307.
13. Lainscak, M., von Haehling, S., Springer, J. and Anker, SD (2007) Biomarkers for chronic heart failure. Heart Failure Monitor, 5, pp. 77-82.
14. Liew, CC (2005) Expressed genome molecular signatures of heart failure. Clinical Chemistry & Laboratory Medicine, 43, pp. 462-469.
15. Miller, WL, Hartman, KA, Burritt, MF, Grill, DE, Rodeheffer, RJ Burnett, JC et al. (2007) Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time. Circulation, 116, pp. 249-257.
16. Nanni, L., Romualdi, C. and Maseri, A. (2006) Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. Journal of Molecular & Cellular Cardiology, 41, pp. 934-948.
17. Park, TS, Yamashita, H., Blaner, WS and Goldberg, IJ (2007) Lipids in the heart: A source of fuel and a source of toxins. Current Opinions in Lipidology, 18, pp. 277-282.
18. Pfaffl, MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research, 29, p. e45.
19. Pomeroy, SL, Tamayo, P., Gaasenbeek, M., Sturla, LM, Angelo, M. McLaughlin, ME et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415, pp. 436-442.
20. Provost, PR, Weech, PK, Tremblay, NM, Marcel, YL and Rassart, E. (1990) Molecular characterization and differential mRNA tissue distribution of rabbit apolipoprotein D. Journal of Lipid Research, 31, pp. 2057-2065.
21. Provost, PR, Villeneuve, L., Weech, PK, Milne, RW, Marcel, YL and Rassart, E. (1991) Localization of the major sites of rabbit apolipoprotein D gene transcription by in situ hybridization. Journal of Lipid Research, 32, pp. 1959-1970.
22. Sarjeant, JM, Lawrie, A., Kinnear, C., Yablonsky, S., Leung, W. Massaeli, H. et al. (2003) Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. Arteriosclerosis. Thrombosis & Vascular Biology, 23, pp. 2172-2177.
23. Spinale, FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiological Reviews, 87, pp. 1285-1342.
24. Spreyer, P., Schaal, H., Kuhn, G., Rothe, T., Unterbeck, A. Olek, K. et al. (1990) Regeneration-associated high level expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve. EMBO Journal, 9, pp. 2479-2484.
25. Tan, FL, Moravec, CS, Li, J., Apperson-Hansen, C., McCarthy, PM, Young, JB and Bond, M. (2002) The gene expression fingerprint of human heart failure. Proceedings of the National Academy of Sciences USA, 99, pp. 11387-11392.
26. Van Gelder, RN, von Zastrow, ME, Yool, A., Dement, WC, Barchas, JD and Eberwine, JH (1990) Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proceedings of the National Academy of Sciences USA, 87, pp. 1663-1667.
27. Vanhoutte, D., Schellings, M., Pinto, Y. and Heymans, S. (2006) Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovascular Research, 69, pp. 604-613.
28. Yang, YH, Dudoit, S., Luu, P., Lin, DM, Peng, V. Ngai, J. et al. (2002) Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Research, 30, p. e15.
29. Zolk, O., Frohme, M., Maurer, A., Kluxen, F-W, Hentsch, B., Zubakov, D., Hoheisel, D., Zucker, IH, Pepe, S. and Eschenhagena, T. (2002) Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure Biochemical and Biophysical Research Communications 293, pp. 1377-1382.